Clinical Trial Update: Study Evaluating Tarlatamab After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer (LS-SCLC) [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating tarlatamab after chemoradiotherapy in limited-stage small cell lung cancer is currently active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Limited-stage Small Cell Lung Cancer
• Small Cell Lung Cancer

Drugs mentioned

• Tarlatamab

Snippet

Sponsor: Amgen | Conditions: Limited Stage Small Cell Lung Cancer, Small Cell Lung Cancer | Phase 3 | Status: ACTIVE_NOT_RECRUITING